The latest financial statement is for the year ending 2025-12-31.
| Cash Flow | 2025-12-31 |
|---|---|
| Segment loss from operations | -26,162 |
| Depreciation and amortization expenses | 2,197 |
| Stock-based compensation | 2,219 |
| Change in fair value of contingent consideration | 5,946 |
| Impairment losses | 14,600 |
| Impairment loss on held for sale assets | 0 |
| Interest expense | -109 |
| Other income, net | 1,011 |
| Income taxes | 0 |
| Net loss | -50,222 |
| Depreciation and amortization expense | 2,190 |
| Amortization of intangible assets | 7 |
| Stock-based compensation | 2,219 |
| Equity compensation for bonus awards and consulting services | 164 |
| Change in fair value of contingent consideration | 5,946 |
| Impairment losses | 14,600 |
| Impairment loss on held for sale assets | 0 |
| Unrealized foreign currency losses (gains) | -185 |
| Accounts receivable | -485 |
| Inventories | 36 |
| Prepaid expenses and other assets | 226 |
| Accounts payable and accrued liabilities | 2,646 |
| Operating lease assets and liabilities | -142 |
| Net cash used in operating activities | -22,184 |
| Proceeds from sale of equipment | 0 |
| Machinery and equipment purchases, and construction in progress | 3,185 |
| Net cash used in investing activities | -3,185 |
| Proceeds from sale of common shares | 29,143 |
| Financing costs to issue common shares | 487 |
| Proceeds from sale of common shares under at-the-market transactions | 0 |
| Financing costs for at-the-market sales | 0 |
| Redemption of series a redeemable convertible preferred shares | 0 |
| Contingent consideration liability payments | 2 |
| Taxes paid related to net share settlement of stock-based awards | 72 |
| Repayment of financing lease obligations | 510 |
| Net provided by financing activities | 28,072 |
| Effect of exchange rate changes on cash and cash equivalents | -120 |
| Net change in cash, cash equivalents and restricted cash | 2,583 |
| Cash, cash equivalents and restricted cash, beginning | 10,336 |
| Cash, cash equivalents and restricted cash, ending | 12,919 |
Insight Molecular Diagnostics Inc. (IMDX)
Insight Molecular Diagnostics Inc. (IMDX)